Pemigatinib (Synonyms: INCB054828) |
| Catalog No.GC32915 |
Pemigatinib (INCB054828) es un inhibidor selectivo de FGFR activo por vÍa oral con IC50 de 0,4 nM, 0,5 nM, 1,2 nM, 30 nM para FGFR1, FGFR2, FGFR3, FGFR4, respectivamente. Pemigatinib tiene el potencial de colangiocarcinoma.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1513857-77-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Pemigatinib is a selective FGFR inhibitor in development for the treatment of patients with cholangiocarcinoma.
[1]. Arudra K, et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct;45(10):786-790.
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *